Eisai Reorganizes R&D Work Into 13 Competitive Units
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to reorganize its research and development operations to make the unit more competitive with the work of other drug makers. Under the plan, MGI Pharma researchers, acquired by Eisai when it bought the firm last year, are to become part of an oncology group, one of 13 units within the R&D division. Each group is to consist of about 100-200 staff ready to operate under the new arrangement in July. The plan includes incentives to the units to compete against each other and other drug makers and each unit is to carry through development from beginning to end. (Click here for more - a subscription may be required